Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy
Bonati U, Hafner P, Schädelin S, Schmid M, Naduvilekoot Devasia A, Schroeder J, Zuesli S, Pohlman U, Neuhaus C, Klein A, Sinnreich M, Haas T, Gloor M, Bieri O, Fischmann A, Fischer D.
Neuromuscul Disord. 2015. 25(9):679-85.
This prospective one year observational study compared quantitative muscle MRI (qMRI) with clinical scores in DMD.
In 20 DMD patients, MFM total and subscores (D1, D2 and D3) were compared to the fat fraction (MFF) of thigh muscle qMRI obtained using the two-point Dixon method.
QMRI shows pathophysiological changes in DMD and might serve as a surrogate outcome measure in clinical trials.
Keywords: Duchenne muscular dystrophy, Outcome measure, Endpoint, Quantitative MRI, Neuromuscular disorders
Articles dans les revues scientifiques
Assessment of disease progression in dysferlinopathy: A 1-year cohort study
Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M,...
Disease duration and disability in dysfelinopathy can be described by muscle imaging using heatmaps and random forests.
Gómez-Andrés D, Díaz J, Munell F, Sánchez-Montáñez Á, Pulido-Valdeolivas I, Suazo L, Garrido C, Quijano-Roy S, Bevilacqua JA. Muscle Nerve. 2019. 59(4), 436-444. The manner in which imaging patterns change over the disease course and with increasing disability in...
Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?
Witherspoon JW, Vasavada R, Logaraj RH, Waite M, Collins J, Shieh C, Meilleur K, Bönnemann C, Jain M. Eur J Paediatr Neurol. 2019. 23 (1), 165-170. The primary objective of this study is to establish the utility of the 2-min walk test (2MWT) in patients with...
Correlation of phenotype with genotype and protein structure in RYR1-related disorders
Todd JJ, Sagar V, Lawal TA, Allen C, Razaqyar MS, Shelton MS, Chrismer IC, Zhang X, Cosgrove MM, Kuo A, Vasavada R, Jain MS, Waite M, Rajapakse D, Witherspoon JW, Wistow G, Meilleur KG. J Neurol. 2018. 265(11), 2506-2524. Variants in the skeletal muscle ryanodine...
Nusinersen in spinal muscular atrophy type 1 patients older than 7 months: A cohort study
Aragon-Gawinska K, Seferian AM, Daron A, Gargaun E, Vuillerot C, Cances C, Ropars J, Chouchane M, Cuppen I, Hughes I, Illingworth M, Marini-Bettolo C, Rambaud J, Taytard J, Annoussamy M, Scoto M, Gidaro T, Servais L. Neurology. 2018. 91(14), e1312-e1318. The study...
Functional assessment tools in children with Pompe disease: A pilot comparative study to identify suitable outcome measures for the standard of care
Ricci F, Brusa C, Rossi F, Rolle E, Placentino V, Berardinelli A, Pagliardini V, Porta F, Spada M, Mongini T. Eur J Paediatr Neurol 2018. 22(6),1103-1109. Progression of Pompe disease was evaluated in 8 young patients. From the results of the study, the authors...